Pathohistological aspects of pulmonary Langerhans cell histiocytosis

Milana Panjković ,
Milana Panjković
Mirjana Miladinović ,
Mirjana Miladinović
Ljiljana Vučković ,
Ljiljana Vučković
Tanja Lakić ,
Tanja Lakić
Aleksandra Ilić ,
Aleksandra Ilić
Aleksandra Lovrenski
Aleksandra Lovrenski

Published: 01.12.2017.

Biochemistry

Volume 34, Issue 3 (2018)

pp. 1656-1663;

https://doi.org/10.5937/matmed1803656p

Abstract

Pulmonary Langerhans cell histiocytosis (PLCH) is a rare disease of unknown etiology, which most commonly affects men, smokers, aged from 20 to 40. It is diagnosed by histological analysis of material obtained by lung biopsy, with immunohistochemical proving of Langerhans cells. The aim of this research is to determine pathohistological characteristics of PLCH and analyzing demographic, clinical and radiological parameters. Retrospective analysis of medical data for 13 patients, proven for PLCH at Institute for Pulmonary diseases of Vojvodina in period of fifteen years. PLCH was found at 9 (69.3%) women and at 4 (30.7%) men, average age 34.7 years. Main clinical symptoms were cough (76.9%) and chest pain (61.5%). Out of 13 patients, 11 (84.6%) were smokers. In most cases PLCH histologically corresponded to the cellular phase of the disease (46.1%), proliferative phase was present at 5 (38.4%), and the fibrotic phase at 2 (15.5%) patients. Immunohistochemically, Langerhans’ cells were positive for presence of CD1a and S-100 antigens in all 13 of analyzed cases, while CD68 antigen was positive in 6 patients. In 6 patients (46.2%) there was disease regression, and at 7 (53.8%) patients the disease progressed despite the applied therapy. In our research, PHLC was more common in younger females, smokers with cough and chest pain. At most of the patients, histologically disease was in the cellular phase. Langerhans cells were positive to presence of CD1a and S100 antigens in all 13 patients. At more than half of the patients the disease progresses despite the applied therapy.

Keywords

References

1.
Cordier JF, Cottin V. Adult Langerhans’ pulmonary cell histiocytosis. 2010.
2.
Lazor R, Etienne-Mastroianni B, Khouatra C, Tazi A, Cottin V, Cordier JF. Progessive diffuse pulmonary Langerhanscell histiocytosis improved by cladribine.
3.
Dauriat G, Mal H, Thabut G, Mornex JF, Bertocchi M, Tronc F, et al. Lung Transplantation for Pulmonary Langerhans’ Cell Histiocytosis: A Multicenter Analysis. Transplantation. 2006;81(5):746–50.
4.
Yağcı B, Varan A, Çağlar M, Söylemezoğlu F, Sungur A, Orhan D, et al. LANGERHANS CELL HISTIOCYTOSIS: Retrospective Analysis of 217 Cases in a Single Center. Pediatric Hematology and Oncology. 2008;25(5):399–408.
5.
Konno S, Hizawa N, Betsuyaku T, Yasuo M, Yamamoto H, Koizumi T, et al. Adult Langerhans Cell Histiocytosis with Independently Relapsing Lung and Liver Lesions That was Successfully Treated with Etoposide. Internal Medicine. 2007;46(15):1231–5.

Citation

Copyright

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Partners